191 related articles for article (PubMed ID: 26705487)
1. Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models.
Nakajima K; Nakata T; Matsuo S; Jacobson AF
Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1138-45. PubMed ID: 26705487
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.
Nakata T; Nakajima K; Yamashina S; Yamada T; Momose M; Kasama S; Matsui T; Matsuo S; Travin MI; Jacobson AF
JACC Cardiovasc Imaging; 2013 Jul; 6(7):772-84. PubMed ID: 23845574
[TBL] [Abstract][Full Text] [Related]
3. Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure.
Nakajima K; Nakata T; Doi T; Kadokami T; Matsuo S; Konno T; Yamada T; Jacobson AF
Eur Heart J Cardiovasc Imaging; 2018 Jul; 19(7):749-756. PubMed ID: 29415138
[TBL] [Abstract][Full Text] [Related]
4. ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study.
Narula J; Gerson M; Thomas GS; Cerqueira MD; Jacobson AF
J Nucl Med; 2015 Jul; 56(7):1011-8. PubMed ID: 26069309
[TBL] [Abstract][Full Text] [Related]
5. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.
Jacobson AF; Senior R; Cerqueira MD; Wong ND; Thomas GS; Lopez VA; Agostini D; Weiland F; Chandna H; Narula J;
J Am Coll Cardiol; 2010 May; 55(20):2212-21. PubMed ID: 20188504
[TBL] [Abstract][Full Text] [Related]
6. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.
Nakajima K; Nakata T; Yamada T; Yamashina S; Momose M; Kasama S; Matsui T; Matsuo S; Travin MI; Jacobson AF
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1673-82. PubMed ID: 24663289
[TBL] [Abstract][Full Text] [Related]
7. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.
Shah AM; Bourgoun M; Narula J; Jacobson AF; Solomon SD
JACC Cardiovasc Imaging; 2012 Nov; 5(11):1139-46. PubMed ID: 23153914
[TBL] [Abstract][Full Text] [Related]
8. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure.
Kyuma M; Nakata T; Hashimoto A; Nagao K; Sasao H; Takahashi T; Tsuchihashi K; Shimamoto K
J Nucl Med; 2004 Feb; 45(2):155-63. PubMed ID: 14960630
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction.
Kasama S; Toyama T; Sumino H; Nakazawa M; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2008 Jun; 49(6):907-14. PubMed ID: 18483106
[TBL] [Abstract][Full Text] [Related]
10. Predicting Risk Versus Predicting Potential Survival Benefit Using 123I-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation: Analysis of Data From the Prospective ADMIRE-HF Study.
Hachamovitch R; Nutter B; Menon V; Cerqueira MD
Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26666380
[TBL] [Abstract][Full Text] [Related]
11. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.
Nagahara D; Nakata T; Hashimoto A; Wakabayashi T; Kyuma M; Noda R; Shimoshige S; Uno K; Tsuchihashi K; Shimamoto K
J Nucl Med; 2008 Feb; 49(2):225-33. PubMed ID: 18199625
[TBL] [Abstract][Full Text] [Related]
12. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.
Nakata T; Wakabayashi T; Kyuma M; Takahashi T; Tsuchihashi K; Shimamoto K
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):186-94. PubMed ID: 15452671
[TBL] [Abstract][Full Text] [Related]
13. Synergistic prognostic implications of left ventricular mechanical dyssynchrony and impaired cardiac sympathetic nerve activity in heart failure patients with reduced left ventricular ejection fraction.
Doi T; Nakata T; Yuda S; Hashimoto A
Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):74-83. PubMed ID: 28158459
[TBL] [Abstract][Full Text] [Related]
14. First determination of the heart-to-mediastinum ratio using cardiac dual isotope (¹²³I-MIBG/⁹⁹mTc-tetrofosmin) CZT imaging in patients with heart failure: the ADRECARD study.
Bellevre D; Manrique A; Legallois D; Bross S; Baavour R; Roth N; Blaire T; Desmonts C; Bailliez A; Agostini D
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1912-9. PubMed ID: 26227533
[TBL] [Abstract][Full Text] [Related]
15. Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan.
Nakajima K; Nakata T
J Nucl Med; 2015 Jun; 56 Suppl 4():11S-19S. PubMed ID: 26033897
[TBL] [Abstract][Full Text] [Related]
16. The relation between cardiac 123I-mIBG scintigraphy and functional response 1 year after CRT implantation.
Verschure DO; Poel E; De Vincentis G; Frantellizzi V; Nakajima K; Gheysens O; de Groot JR; Verberne HJ
Eur Heart J Cardiovasc Imaging; 2021 Jan; 22(1):49-57. PubMed ID: 32259839
[TBL] [Abstract][Full Text] [Related]
17. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis.
Verschure DO; Veltman CE; Manrique A; Somsen GA; Koutelou M; Katsikis A; Agostini D; Gerson MC; van Eck-Smit BL; Scholte AJ; Jacobson AF; Verberne HJ
Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):996-1003. PubMed ID: 24686260
[TBL] [Abstract][Full Text] [Related]
18. Exercise duration and peak systolic blood pressure are predictive of mortality in ambulatory patients with mild-moderate chronic heart failure.
Williams SG; Jackson M; Ng LL; Barker D; Patwala A; Tan LB
Cardiology; 2005; 104(4):221-6. PubMed ID: 16158008
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure.
Kuramoto Y; Yamada T; Tamaki S; Okuyama Y; Morita T; Furukawa Y; Tanaka K; Iwasaki Y; Yasui T; Ueda H; Okada T; Kawasaki M; Levy WC; Komuro I; Fukunami M
Am J Cardiol; 2011 Apr; 107(8):1185-90. PubMed ID: 21349482
[TBL] [Abstract][Full Text] [Related]
20. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
